Rosetta Genomics top executive said this week that the firm expects to forge at least one strategic partnership by year end, although he did not specify whether it would be around its diagnostics, drug research biomarker, or therapeutics efforts.
Rosetta Genomics said that its chief commercialization officer would resign as the company settles into its latest change in corporate direction. But the company is not the only player in the RNAi/microRNA space to experience changes to its management lineup.
"We've established the intellectual property portfolio and basis to be an integrated personalized medicine company focused in nucleic acid therapeutics and diagnostics," President and CEO Michael French told Gene Silencing News.
Today's announcement and previously obtained exclusive rights to CRN technology for both therapeutics and diagnostics gives MDRNA one of the few intellectual property portfolios that support a nucleic acid-based personalized medicine platform and the ability to pursue proprietary nucleic acid-based therapeutics and diagnostics, the company said.
"We believe [the FAP drug] is a product that the combined company could commercialize with a small specialty sales force [with] minimal sales and marketing infrastructure," MDRNA's President and CEO Michael French said this week.